Related Experiment Video
Updated: Apr 15, 2026
12:47
Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages
Published on: November 3, 2014
12.3K
CD44-targeted immunoliposomes for IL-1β knockdown modulate macrophage-mediated inflammation.
Haly Shukla1, Simran Nasra1, Milonee Patel1
1Biological and Life Sciences, School of Arts & Sciences, Ahmedabad University, Central Campus, Ahmedabad, Gujarat, India.
Communications Biology
|April 13, 2026
Summary
This study introduces siIL-1β-anti-CD44-Liposomes (SIL) for chronic inflammation. SIL effectively reduces inflammatory gene and protein expression, offering a promising targeted therapy for inflammatory disorders.
Area of Science:
- Biotechnology
- Immunology
- Nanomedicine
Background:
- Chronic inflammation underlies numerous critical diseases.
- Targeted gene knockdown offers a novel therapeutic strategy for inflammation control.
Purpose of the Study:
- To investigate siIL-1β-anti-CD44-Liposomes (SIL) as a targeted anti-inflammatory therapy.
- To evaluate SIL's efficacy in gene-specific knockdown of IL-1β mRNA via CD44-targeted immunoliposomes.
Main Methods:
- Development of CD44-targeted immunoliposomes encapsulating siIL-1β.
- Characterization of SIL size, morphology, and drug release kinetics.
- Validation of SIL efficacy in cellular and preclinical inflammation models.
Main Results:
- SIL exhibited optimal size (131.1 nm) and sustained release of siIL-1β.
- Significant reduction in IL-1β and TNF-α at gene and protein levels observed.
- SIL modulated macrophage-T cell interactions and decreased systemic inflammatory markers like C-reactive protein.
Conclusions:
- siIL-1β-anti-CD44-liposomes show significant therapeutic potential for chronic inflammatory disorders.
- SIL demonstrates multifaceted immunomodulatory effects at tissue and cytokine levels.
- Targeted delivery via SIL offers a promising approach for managing inflammation.
